AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05636462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global postural re-education program
Description: Different postures of global re-education programs are used and stretch is applied in these postures.~3 sessions per week are given and each session time is 40 minutes. Treatment is given for 4 weeks.
Study NCT05636462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Isometrics and stretching is used as conventional treatment. 3 sessions per week are given and each session time is 40 minutes. Treatment is given for 4 weeks.
Study NCT06366269 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: pelvic floor with biofeedback
Study NCT05135546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant nonimmunogenic staphylokinase
Description: 15 mg of drug reconstituted in 6 ml of 0.9% solution of NaCl for inhalation Other Name: Fortelyzin®
Study NCT05135546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 ml of 0.9% solution of NaCl for inhalation
Study NCT00347997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 217z Laser
Description: LASIK correction of myopia and myopic astigmatism
Study NCT04866121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: A standardized acupuncture protocol will be administered
Study NCT04866121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: A standardized acupuncture protocol will be administered
Study NCT04757818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.07% cetylpyridinium chloride (CPC) in mouthwash
Description: A mouthwash and gargles with 15 ml of 0.07% cetylpyridinium chloride (CPC) in mouthwash for 1 minute.
Study NCT04757818 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water with the same colorant as the experimental product
Description: A mouthwash and gargles with 15 ml of distilled water for 1 minute
Study NCT05269147 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sphenopalatine Ganglion Block (SPGB)
Description: The SPGB will be done after the patient is generally anesthetized and will be performed by the operating surgeon using a transnasal endoscopic approach through the posterior and over the middle turbinate tail in the pterygopalatine fossa.~The patient will be placed in the supine position with head extension. The prepared solution (4 ccs 2% lidocaine or 0.5% bupivacaine or normal saline and 1 cc 8 mg dexamethasone) will be given (2,5 cc) to each side of the nose.~The surgery was started 10 minutes after the application of SPBG to allow sufficient time for the block to develop.
Study NCT05269147 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sphenopalatine Ganglion Block (SPGB)
Description: The SPGB will be done after the patient is generally anesthetized and will be performed by the operating surgeon using a transnasal endoscopic approach through the posterior and over the middle turbinate tail in the pterygopalatine fossa.~The patient will be placed in the supine position with head extension. The prepared solution (4 ccs 2% lidocaine or 0.5% bupivacaine or normal saline and 1 cc 8 mg dexamethasone) will be given (2,5 cc) to each side of the nose.~The surgery was started 10 minutes after the application of SPBG to allow sufficient time for the block to develop.
Study NCT05250401 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: liver functions and thyroid functions
Description: laboratory tests
Study NCT04886258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DFV890
Description: DFV890
Study NCT04886258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05587244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners
Description: Primary and/or Revision total hip arthroplasty with the G7 Freedom Constrained Vivacit-E Liners
Study NCT06289504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Cagrilintide will be administered subcutaneously once weekly.
Study NCT06289504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide will be administered subcutaneously once weekly.
Study NCT06289504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin will be administered as a single dose orally 2 times during the study.
Study NCT06289504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin will be administered as a single dose orally 2 times during the study.
Study NCT05256706 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SomaSignal Informed Medical Management SSCVD
Description: For participants randomized to the Informed arm, the SSCVD test results will be provided to the participant's clinicians approximately 2-4 weeks after the baseline blood draw. Clinicians will discuss results with the participant and make adjustments to the care plan as needed based on the SSCVD test results within 50 days of receiving results. Clinicians may advise participants to (i) either change the doses of existing medications within existing guidelines, (ii) prescribe additional guideline-based medications, (iii) advise additional lifestyle interventions, or (iv) advise no change. This information will be documented in the case report forms. This test is neither intended to diagnose cardiovascular disease (CVD) nor replace the standard of care protocols for this disease. The physician should not rely solely on this information to make a decision on the best course of action for this patient.
Study NCT05256706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Clinicians will provide the standard of care based on routine test results and without the SSCVD results. The SSCVD and SomaSignal Metabolic Factor Panel results from participants from both the baseline and 6-month period will be provided to the study team at the 6-month study visit. The SomaSignal Metabolic Factor tests include evaluation of Liver Fat, Glucose Tolerance, Kidney Function, Alcohol Impact, Cardiorespiratory Fitness/oxygen consumption (VO2) max, Resting Energy Rate, Body Fat Percentage, Visceral Fat, and Lean Body Mass. Any recommendations made to the participant by the physicians, based on obtaining the aforementioned test results will be collected.
Study NCT05766735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine Care + Glycemic Excursion Minimization (RC+GEM)
Description: In addition to receiving routine care, participants will receive GEM, a structured, self-directed, and personalized program that will allow participants with pre-diabetes to improve their metabolic status by illustrating the effects of their routine food and physical activity choices on their blood glucose levels and variability.
Study NCT05766735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care (RC)
Description: RC participants will meet with their primary care provider to determine the best diabetes medication and proper dose. The participant will be allowed to change medications, or use a combination of medications, that is best suited for their care during the duration of the study. The study team will not influence these decisions.
Study NCT05379595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as intravenous infusion.
Study NCT05379595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amivantamab
Description: Amivantamab will be administered as intravenous infusion.
Study NCT05379595 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Fluorouracil will be administered as intravenous infusion.
Study NCT05379595 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Leucovorin will be administered as intravenous infusion.
Study NCT05379595 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered as intravenous infusion.
Study NCT05379595 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan will be administered as intravenous infusion.
Study NCT06299540 — intervention group
Intervention type: BEHAVIORAL
Intervention: Individual Physical Activity Intervention (IPAI)
Description: No drug will be administered as a part of this study. The intervention will consist in an IPAI provided to participants for 6 months to practice physical activity in addition to their medical treatment in routine clinical practice settings. IPAI will be an adaptive program and will comprise two periods, the first period consisting in a supervised 4-month program and the second one in an unsupervised 2-month program to achieve greater autonomy.
Study NCT06299540 — intervention group
Intervention type: DRUG
Intervention: Ibrutinib
Description: No drug will be administered as a part of this study. Participants received ibrutinib as per their routine clinical practice settings.
Study NCT05182827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tactile stimulation
Description: The experimental task aims to evaluate the hedonic nature of an affective touch by tactile stimulation.~It consists in stimulating two adjacent regions of the left forearm, delimited and marked, of 9 cm x 4 cm each. In order to limit habituation, the stimulation areas will be alternated.~To stimulate these areas, the investigator (previously trained) strokes the participant with a brush at an optimal speed to stimulate the C-fibers (3 cm/s; slow speed) or not (18 cm/s; fast speed).~Touch will consist of 30 seconds blocks of stimulation, performed on one of the two identified areas, from the elbow to the wrist. In total, 6 stimulation blocks will be done (3 slow and 3 fast), the order and location of which will be random in order to limit habituation.~This stimulation is completely painless. After each block, the participant will evaluate the intensity of the stimulation and its pleasantness.
Study NCT06556940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMN-401
Description: Orally delivered tablets and capsules
Study NCT05957536 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D3L-001
Description: Intravenous administration
Study NCT05071664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered as a SC injection.
Study NCT05071664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guselkumab
Description: Guselkumab will be administered as a SC injection.
Study NCT05071664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Golimumab will be administered as a SC injection.
Study NCT05071664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a SC injection.
Study NCT04779918 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OviTex Reinforced Tissue Matrix
Description: All study subjects will receive OviTex. All OviTex Reinforced Tissue Matrices are intended for use as a surgical mesh to reinforce or repair soft tissue where weakness exists.
Study NCT06049017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 tablet will be administered orally.
Study NCT06049017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet will be administered orally.
Study NCT06260163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Subcutaneous
Description: Guselkumab will be administered subcutaneously.
Study NCT06260163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Intravenous
Description: Guselkumab will be administered intravenously.
Study NCT04064164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speeko for Elderspeak
Description: Speeko for Elderspeak is a communication feedback IOS application.
Study NCT06059339 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Procedure/Surgery: Regional Block Comparison Comparing postoperative pain and opioid consumption in groups
Description: Procedure/Surgery: Regional Block Comparison Comparing postoperative pain and opioid consumption in groups
Study NCT05862285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Study NCT05862285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab in combination with atezolizumab will be administered at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Study NCT05862285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as a monotherapy and in combination with tiragolumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Study NCT06489106 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activity based upper extremity training with and without stimulation
Description: Activity-based upper extremity training (AB-UET) will be administered 5d/week and 1 hour 30 minutes/session. For AB-UET+ stimulation (scTS), UE tasks will be repeated with and without scTS so that scTS is administered intermittently for the duration of \~ 10 minute/bouts.
Study NCT06489106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity based upper extremity training with and without stimulation
Description: Activity-based upper extremity training (AB-UET) will be administered 5d/week and 1 hour 30 minutes/session. For AB-UET+ stimulation (scTS), UE tasks will be repeated with and without scTS so that scTS is administered intermittently for the duration of \~ 10 minute/bouts.
Study NCT06045663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laminectomy without lateral mass fixation
Description: patient will divided into two group the first group will undergo cervical laminectomy without lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation
Study NCT06045663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laminectomy with lateral mass fixation
Description: patient will divided into two group the first group will undergo cervical laminectomy without lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation
Study NCT06179069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-1310
Description: Drug: ZL-1310
Study NCT06179069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Drug Atezolizumab
Study NCT06179069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Drug Carboplatin
Study NCT06316297 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acne mRNA vaccine
Description: Pharmaceutical form:Liquid suspension for injection-Route of administration:intramuscular
Study NCT06316297 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Liquid solution for injection-Route of administration:intramuscular
Study NCT06465277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dobutamine stress CMR
Description: Dobutamine stress testing will be undertaken in keeping with local departmental clinical guidelines with a graded increase in dobutamine infusion up to a maximum of 10microgram/kg/min. The patients' medications will be managed in keeping with the usual clinical practice and departmental guidelines.~At rest and on each graded level of dobutamine infusion we will collect cine loops of the cardiac cycle including a short-axis stack of the ventricles, a four-chamber view and flow imaging perpendicular to the main, left and right pulmonary arteries.~Post-processing will be dual reported by blinded observers using the Argus analysis software (Siemens) according to a standardised protocol. A safety report of each CMR scan will be generated by a consultant cardiologist, any abnormalities identified will be referred to the appropriate medical speciality and highlighted to the patient's clinical team.
Study NCT06465277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac biomarker sample
Description: blood samples will be collected pre-operatively, in recovery, on post-operative days 1 and 2, and at 4-8 weeks post-operatively
Study NCT04752215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765049
Description: BI 765049
Study NCT04752215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezabenlimab
Description: ezabenlimab
Study NCT05553145 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Autoimmune Antibody Assays
Description: GAD-65, Islet cell-Ab, IA-2 Ab, anti-insulin Ab, and ZnTn8 Ab
Study NCT06246396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline Hydrochloride
Description: Minocycline Hydrochloride 100 mg twice daily
Study NCT06246396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05988788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epigallocatechin-3-gallate
Description: to be used as a root canal irrigant
Study NCT05988788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sodium hypochlorite
Description: to be used as a root canal irrigant
Study NCT05972655 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Modified short-course radiotherapy
Description: radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes: 25Gy/5Fx
Study NCT05972655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: PD-1 antibody (Tislelizumab): 200mg d1 q3w
Study NCT05972655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 d1-14 q3w
Study NCT05972655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2 d1 q3w
Study NCT05546866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Subjects successfully enrolled into the study will receive 80mg osimertinib QD p.o. until completion of planned treatment duration, recurrence of disease, or other treatment discontinuation criteria is met. The maximum treatment duration period is 3 years.
Study NCT06264986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ashwagandha
Description: The intervention will be 600mg of KSM-66, a branded supplement derived from the root extract of the herb ashwagandha, with a consistent rate of 5% withanolides for 28 days. It is the most clinically studied extract of the herb and is the only type of ashwagandha to receive third party testing certification (Informed Sport, Informed Ingredient, Banned Substances Control Group, Clean Label Project). The laboratory where the product is made, Ixoreal Biomed, has received Current Good Laboratory Practices (cGLP), quality controlled and tested against heavy metals and pesticides.
Study NCT06264986 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 600mg chickpea flour in a hydroxypropyl methylcellulose capsule, once a day for 28 days
Study NCT05086250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).
Study NCT05086250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).
Study NCT05086250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
Study NCT05086250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
Study NCT06133842 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intra-op EEG and CO data collection
Description: Intra-op EEG and CO data will be collected non-invasively. This will not guide or affect patient care of procedure in any way.
Study NCT05651022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decoy20
Description: Decoy20 is a novel, systemically administered multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy.
Study NCT06393114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented oat-based product
Description: Participants will incorporate a novel fermented product into their habitual diet for three weeks. In addition, the consumption of dairy and plant-based dairy alternatives is restricted. Cereal product consumption, specifically bread and porridge, is slightly restricted to prevent gastrointestinal symptoms caused by the increased intake of dietary fibre. Participants will receive dietary guidance on how to follow the intervention diet, as well as potential supplement recommendations provided by the authorized nutritionist.